PMID- 22009442
OWN - NLM
STAT- MEDLINE
DCOM- 20120917
LR  - 20211020
IS  - 1573-2576 (Electronic)
IS  - 0360-3997 (Linking)
VI  - 35
IP  - 3
DP  - 2012 Jun
TI  - Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) mediates p38 
      mitogen-activated protein kinase activation and signal transduction in peripheral 
      blood mononuclear cells from patients with lupus nephritis.
PG  - 935-43
LID - 10.1007/s10753-011-9396-3 [doi]
AB  - Forty-two patients with systemic lupus erythematosus (SLE), including 26 patients 
      with renal damage and 16 without, and 20 healthy controls were included in the 
      study. The isolated peripheral blood mononuclear cells (PBMCs) were treated with 
      a p38 inhibitor (SB203580) or anti-tumor necrosis factor-like weak inducer of 
      apoptosis (TWEAK) mAb, with or without phytohemagglutinin/phorbol myristate 
      acetate (PHA/PMA) stimulation. Western blot experiments were used to evaluate the 
      protein expression of TWEAK and p38 MAPK in PBMCs .Next, the contents of 
      interleukin-10 (IL-10) and monocyte chemoattractant protein-1 (MCP-1) in the 
      supernatant were measured by ELISA. The results showed that expression of TWEAK 
      protein in PBMCs from lupus nephritis patients was significantly higher than that 
      from SLE patients without renal damage and healthy controls. PHA/PMA simulation 
      could upregulate the productions of TWEAK and p-p38MAPK in PBMCs from patients 
      with SLE. Anti-TWEAK mAb treatment downregulated both TWEAK and p-p38 MAPK 
      expression in PBMCs, as well as IL-10 and MCP-1 in the supernatant; SB203580 had 
      the same effect on cytokine production in PBMC, but had no effect on the 
      expression of TWEAK. Our results suggested that TWEAK-p38 MAPK-IL-10, MCP-1 
      signaling pathway in PBMC played an important pathogenic role in lupus nephritis.
FAU - Zhi-Chun, Liu
AU  - Zhi-Chun L
AD  - Department of Rheumatology and Immunology, The Second Affiliated Hospital of 
      Suzhou University, Suzhou, China.
FAU - Qiao-Ling, Zhou
AU  - Qiao-Ling Z
FAU - Zhi-Qin, Liu
AU  - Zhi-Qin L
FAU - Xiao-Zhao, Li
AU  - Xiao-Zhao L
FAU - Xiao-xia, Zuo
AU  - Xiao-xia Z
FAU - Rong, Tang
AU  - Rong T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Imidazoles)
RN  - 0 (Phytohemagglutinins)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (TWEAK Receptor)
RN  - 0 (Tumor Necrosis Factors)
RN  - 130068-27-8 (Interleukin-10)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - OU13V1EYWQ (SB 203580)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Monoclonal/immunology
MH  - Cells, Cultured
MH  - Chemokine CCL2/metabolism
MH  - Female
MH  - Humans
MH  - Imidazoles/pharmacology/therapeutic use
MH  - Interleukin-10/metabolism
MH  - Leukocytes, Mononuclear/*metabolism
MH  - Lupus Erythematosus, Systemic/blood/immunology/*metabolism
MH  - Lupus Nephritis/blood/immunology/*metabolism
MH  - MAP Kinase Signaling System
MH  - Male
MH  - Middle Aged
MH  - Phytohemagglutinins/pharmacology
MH  - Pyridines/pharmacology/therapeutic use
MH  - Receptors, Tumor Necrosis Factor/immunology/*metabolism
MH  - TWEAK Receptor
MH  - Tetradecanoylphorbol Acetate/pharmacology
MH  - Tumor Necrosis Factors/immunology/*metabolism
MH  - Young Adult
MH  - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism
EDAT- 2011/10/20 06:00
MHDA- 2012/09/18 06:00
CRDT- 2011/10/20 06:00
PHST- 2011/10/20 06:00 [entrez]
PHST- 2011/10/20 06:00 [pubmed]
PHST- 2012/09/18 06:00 [medline]
AID - 10.1007/s10753-011-9396-3 [doi]
PST - ppublish
SO  - Inflammation. 2012 Jun;35(3):935-43. doi: 10.1007/s10753-011-9396-3.